Cargando…

Vascular CXCR4 Expression – a Novel Antiangiogenic Target in Gastric Cancer?

BACKGROUND: G-protein-coupled receptors (GPCRs) are prime candidates for novel cancer prevention and treatment strategies. We searched for differentially expressed GPCRs in node positive gastric carcinomas. METHODOLOGY/PRINCIPAL FINDINGS: Differential expression of GPCRs in three node positive vs. t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ingold, Barbara, Simon, Eva, Ungethüm, Ute, Kuban, Ralf-Jürgen, Müller, Berit M., Lupp, Amelie, Neumann, Ulf, Ebert, Matthias P. A., Denkert, Carsten, Weichert, Wilko, Schulz, Stefan, Röcken, Christoph
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851611/ https://www.ncbi.nlm.nih.gov/pubmed/20386750 http://dx.doi.org/10.1371/journal.pone.0010087

Ejemplares similares

CXC Chemokine Receptor 7 (CXCR7) Regulates CXCR4 Protein Expression and Capillary Tuft Development in Mouse Kidney
por: Haege, Sammy, et al.
Publicado: (2012)

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)

CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy–Resistant Glioblastoma
por: Angara, Kartik, et al.
Publicado: (2018)

Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas
por: Kaemmerer, Daniel, et al.
Publicado: (2017)

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019)

Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms
por: Kaemmerer, Daniel, et al.
Publicado: (2014)

Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies
por: Werner, Christoph, et al.
Publicado: (2020)

Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies
por: Czajkowski, Max, et al.
Publicado: (2022)

Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets
por: Kaemmerer, Daniel, et al.
Publicado: (2017)

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo
por: Lehmann, Annika, et al.
Publicado: (2009)

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer
por: Devapatla, Bharat, et al.
Publicado: (2015)

Reassessment of SST4 Somatostatin Receptor Expression Using SST4-eGFP Knockin Mice and the Novel Rabbit Monoclonal Anti-Human SST4 Antibody 7H49L61
por: Lupp, Amelie, et al.
Publicado: (2021)

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
por: Fritzsche, Florian R, et al.
Publicado: (2008)

Classical pathology and mutational load of breast cancer – integration of two worlds
por: Budczies, Jan, et al.
Publicado: (2015)

Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients
por: Baccelli, Irène, et al.
Publicado: (2014)

Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover
por: Denkert, Carsten, et al.
Publicado: (2008)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
por: Stadlbauer, Andreas, et al.
Publicado: (2017)

An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas
por: Noske, Aurelia, et al.
Publicado: (2011)

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007)

Vascular co‐option and vasculogenic mimicry mediate resistance to antiangiogenic strategies
por: Pezzella, Francesco, et al.
Publicado: (2020)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

TGF-β Superfamily Receptors—Targets for Antiangiogenic Therapy?
por: Otten, Jasmin, et al.
Publicado: (2010)

Life-Threatening Mediastinal Teratoma of Infant Requiring Emergency Surgical Removal
por: Piber, Nicole, et al.
Publicado: (2022)

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2009)

Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61
por: Ehms, Blanca, et al.
Publicado: (2022)

Monitoring vascular normalization induced by antiangiogenic treatment with 18F‐fluoromisonidazole‐PET
por: Hernández-Agudo, Elena, et al.
Publicado: (2015)

Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells
por: Winter, Ursula, et al.
Publicado: (2016)

Who Is at Risk for Diagnostic Discrepancies? Comparison of Pre- and Postmortal Diagnoses in 1800 Patients of 3 Medical Decades in East and West Berlin
por: Wittschieber, Daniel, et al.
Publicado: (2012)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017)

Antiangiogenic Effect of Alkaloids
por: Alasvand, Masoud, et al.
Publicado: (2019)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235
por: Schulz, Stefan, et al.
Publicado: (2015)

Administration of a CXCL12 Analog in Endotoxemia Is Associated with Anti-Inflammatory, Anti-Oxidative and Cytoprotective Effects In Vivo
por: Seemann, Semjon, et al.
Publicado: (2015)

Administration of AMD3100 in endotoxemia is associated with pro-inflammatory, pro-oxidative, and pro-apoptotic effects in vivo
por: Seemann, Semjon, et al.
Publicado: (2016)

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment
por: Budczies, Jan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mhd512094s4v0ic8a8vips44g1